PMC:7029759 / 28692-28897 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"745","span":{"begin":37,"end":41},"obj":"Gene"},{"id":"746","span":{"begin":137,"end":141},"obj":"Gene"},{"id":"755","span":{"begin":100,"end":104},"obj":"Species"},{"id":"767","span":{"begin":189,"end":201},"obj":"Disease"}],"attributes":[{"id":"A745","pred":"tao:has_database_id","subj":"745","obj":"Gene:70008"},{"id":"A746","pred":"tao:has_database_id","subj":"746","obj":"Gene:70008"},{"id":"A755","pred":"tao:has_database_id","subj":"755","obj":"Tax:10090"},{"id":"A767","pred":"tao:has_database_id","subj":"767","obj":"MESH:D006973"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Indeed, the half-life of recombinant ACE2 was extended from less than two hours to over one week in mice when formatted as a recombinant ACE2-Fc therapy in a study evaluating treatment for hypertension 63."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T512","span":{"begin":37,"end":41},"obj":"G_3;PG_10;PR:000003622"},{"id":"T511","span":{"begin":100,"end":104},"obj":"NCBITaxon:10088"},{"id":"T510","span":{"begin":137,"end":141},"obj":"G_3;PG_10;PR:000003622"}],"text":"Indeed, the half-life of recombinant ACE2 was extended from less than two hours to over one week in mice when formatted as a recombinant ACE2-Fc therapy in a study evaluating treatment for hypertension 63."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T103","span":{"begin":189,"end":201},"obj":"Disease"}],"attributes":[{"id":"A103","pred":"mondo_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"}],"text":"Indeed, the half-life of recombinant ACE2 was extended from less than two hours to over one week in mice when formatted as a recombinant ACE2-Fc therapy in a study evaluating treatment for hypertension 63."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T278","span":{"begin":123,"end":124},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T279","span":{"begin":142,"end":144},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T280","span":{"begin":156,"end":157},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Indeed, the half-life of recombinant ACE2 was extended from less than two hours to over one week in mice when formatted as a recombinant ACE2-Fc therapy in a study evaluating treatment for hypertension 63."}

{"project":"LitCovid-sentences","denotations":[{"id":"T185","span":{"begin":0,"end":205},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Indeed, the half-life of recombinant ACE2 was extended from less than two hours to over one week in mice when formatted as a recombinant ACE2-Fc therapy in a study evaluating treatment for hypertension 63."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T19","span":{"begin":189,"end":201},"obj":"Phenotype"}],"attributes":[{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"Indeed, the half-life of recombinant ACE2 was extended from less than two hours to over one week in mice when formatted as a recombinant ACE2-Fc therapy in a study evaluating treatment for hypertension 63."}